Bruker to buy PhenomeX for $108M

Scientific instruments maker Bruker has agreed to buy PhenomeX for about $108 million, marking its entry into the market for functional single-cell biology research systems. PhenomeX supplies an analysis platform that enables researchers to characterize tens of thousands of single cells in parallel. Bruker said the technology will support its customers’ abilities to discover new antibodies and accelerate development and manufacturing of cell and gene therapies.

PhenomeX CEO and director Siddhartha Kadia stated: “By joining forces with Bruker, a respected and innovative global leader in life science research tools, we will not only enhance PhenomeX’s differentiated, high-value technologies but also our customers’ abilities to discover novel antibodies and accelerate development and manufacturing of cell and gene therapies.”

Bruker NANO Group president Dr Mark Munch stated: “The unique single-cell analysis platforms of PhenomeX are enabling researchers to more rapidly and precisely unlock new insights in functional cell biology research leading to important discoveries across the large and rapidly growing markets of antibody therapeutics, cell line development, cell therapy and gene therapy.”

The deal is expected to close in the fourth quarter.

For our upcoming conference visit – https://virtueinsight.com/upcoming-conferences/